Completed NA INTERVENTIONAL 1-arm NCT04324489

DAS181 for Severe COVID-19: Compassionate Use

Sponsor: Ansun Biopharma, Inc.

Conditions COVID-19

Interventions DAS181

Updated 6 times since 2020 Last updated: May 1, 2020 Started: Mar 6, 2020 Primary completion: Apr 16, 2020 Completion: Apr 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on COVID-19, this trial is completed. The trial is conducted by Ansun Biopharma, Inc. and has accumulated 6 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2020 — Jan 2021 [monthly]

Completed NA

Status: Recruiting → Completed
May 2020 — Jun 2020 [monthly]

Recruiting NA

▶ Show 1 earlier version

Apr 2020 — May 2020 [monthly]

Recruiting NA

First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ansun Biopharma, Inc.
Renmin Hospital of Wuhan University

Data source: Renmin Hospital of Wuhan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China